GMAB – Genmab A/S

Genmab A/S

GMAB

$30.48

Name : Genmab A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $18,762,618,880.00

EPSttm : 2.28

Genmab A/S

$30.48

0.71%

$0.215

Float Short %

1.71

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

EPS Last/This Y

0.18

EPS This/Next Y

-0.62

Price

30.26

Target Price

33.81

Analyst Recom

1.89

Performance Q

29.21

Relative Volume

0.68

Beta

0.9

Ticker: GMAB

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	GMAB	30.54	0.22	0.04	2422
2025-10-21	GMAB	30.14	0.22	0.14	2468
2025-10-22	GMAB	29.91	0.22	0.00	2499
2025-10-23	GMAB	29.91	0.20	0.00	2771
2025-10-24	GMAB	29.89	0.19	0.03	2795
2025-10-27	GMAB	29.02	0.19	0.00	2825
2025-10-28	GMAB	29.12	0.19	0.00	2902
2025-10-29	GMAB	28.95	0.19	0.27	2914
2025-10-30	GMAB	28.67	0.19	0.04	2924
2025-10-31	GMAB	28.6	0.19	0.07	2928
2025-11-03	GMAB	28.7	0.19	0.01	2946
2025-11-04	GMAB	28.75	0.19	0.08	2945
2025-11-05	GMAB	29.22	0.19	0.00	2962
2025-11-06	GMAB	28.83	0.17	0.02	3131
2025-11-07	GMAB	28.66	0.16	0.74	3313
2025-11-10	GMAB	29.07	0.17	0.03	3220
2025-11-11	GMAB	30.32	0.17	0.01	3232
2025-11-12	GMAB	30.48	0.17	0.09	3328
2025-11-13	GMAB	30.23	0.17	0.02	3356
2025-11-14	GMAB	30.26	0.17	0.02	3362
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	GMAB	30.54	56.4	6.2	1.67
2025-10-21	GMAB	30.13	56.4	74.9	1.67
2025-10-22	GMAB	29.92	59.2	126.1	1.69
2025-10-23	GMAB	29.88	59.2	123.2	1.69
2025-10-24	GMAB	29.88	59.2	107.3	1.69
2025-10-27	GMAB	29.02	59.2	81.5	1.69
2025-10-28	GMAB	29.13	59.2	89.0	1.69
2025-10-29	GMAB	28.96	59.2	117.0	1.69
2025-10-30	GMAB	28.67	59.2	100.7	1.71
2025-10-31	GMAB	28.61	59.2	135.7	1.71
2025-11-03	GMAB	28.71	59.2	164.0	1.71
2025-11-04	GMAB	28.77	59.2	145.9	1.71
2025-11-05	GMAB	29.22	59.2	171.5	1.71
2025-11-06	GMAB	28.84	59.2	150.0	1.71
2025-11-07	GMAB	28.66	59.2	248.2	1.71
2025-11-10	GMAB	29.06	-48.0	-31.2	1.71
2025-11-11	GMAB	30.31	-48.0	31.6	1.88
2025-11-12	GMAB	30.48	-48.0	150.7	1.88
2025-11-13	GMAB	30.24	-48.0	81.8	1.88
2025-11-14	GMAB	30.26	-48.0	89.8	1.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	GMAB	0	0.37	0.90
2025-10-21	GMAB	0	0.37	0.90
2025-10-22	GMAB	0	0.37	0.90
2025-10-23	GMAB	0	0.37	0.90
2025-10-24	GMAB	0	0.37	0.90
2025-10-27	GMAB	0	0.36	1.08
2025-10-28	GMAB	0	0.36	1.08
2025-10-29	GMAB	0.00	0.36	1.08
2025-10-30	GMAB	0.00	0.36	1.08
2025-10-31	GMAB	0.00	0.36	1.08
2025-11-03	GMAB	0	0.30	1.08
2025-11-04	GMAB	0	0.30	1.08
2025-11-05	GMAB	0	0.30	1.08
2025-11-06	GMAB	0	0.30	1.08
2025-11-07	GMAB	0	0.30	1.08
2025-11-10	GMAB	0	0.32	0
2025-11-11	GMAB	0	0.32	1.08
2025-11-12	GMAB	0	0.32	1.71
2025-11-13	GMAB	0	0.32	1.71
2025-11-14	GMAB	0	0.32	1.71
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.65

Avg. EPS Est. Current Quarter

0.43

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

0.32

Beta

0.9

Average Sales Estimate Current Quarter

6513

Average Sales Estimate Next Quarter

6006

Fair Value

36.53

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

38.3

Max Drawdown 5-Year %

-63.1

Target Price

33.81

P/E

12.85

Forward P/E

18.31

PEG

1.51

P/S

5.19

P/B

3.24

P/Free Cash Flow

14.92

EPS

2.35

Average EPS Est. Cur. Y

1.88

EPS Next Y. (Est.)

1.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

41.34

Relative Volume

0.68

Return on Equity vs Sector %

-1.8

Return on Equity vs Industry %

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.2

EBIT Estimation

89.8

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2681

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

Novo Nordisk A/S

NVO

$48.44

Name : Novo Nordisk A/S

Sector : Healthcare

Industry: Drug Manufacturers - General

Mark. Cap: $215,219,945,472.00

EPSttm : 3.63

Novo Nordisk A/S

$48.44

0.36%

$0.175

Float Short %

0.84

Margin Of Safety %

Put/Call OI Ratio

0.75

EPS Next Q Diff

EPS Last/This Y

19.37

EPS This/Next Y

0.01

Price

48.25

Target Price

63.25

Analyst Recom

2.06

Performance Q

-10.21

Relative Volume

0.8

Beta

0.67

Ticker: NVO

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	NVO	55.74	0.77	0.67	1195188
2025-10-21	NVO	54.8	0.77	0.53	1248404
2025-10-22	NVO	53.37	0.77	0.82	1274147
2025-10-23	NVO	53.23	0.77	0.70	1310141
2025-10-24	NVO	52.95	0.78	0.51	1326320
2025-10-27	NVO	52.9	0.79	0.77	1290705
2025-10-28	NVO	52.06	0.81	0.82	1334462
2025-10-29	NVO	51.4	0.81	1.32	1361982
2025-10-30	NVO	50.05	0.83	0.59	1405852
2025-10-31	NVO	49.4	0.82	0.55	1460467
2025-11-03	NVO	49.12	0.81	0.55	1406095
2025-11-04	NVO	48.25	0.80	0.71	1457520
2025-11-05	NVO	48.47	0.80	0.48	1536958
2025-11-06	NVO	46.54	0.80	0.25	1610969
2025-11-07	NVO	45.58	0.78	1.09	1656166
2025-11-10	NVO	45.96	0.81	0.40	1579618
2025-11-11	NVO	49.17	0.80	0.29	1643519
2025-11-12	NVO	50.27	0.79	0.46	1685426
2025-11-13	NVO	49.21	0.77	0.27	1733361
2025-11-14	NVO	48.11	0.75	0.49	1787813
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	NVO	55.74	-29.7	420.4	23.56
2025-10-21	NVO	54.78	-29.7	-1034.4	23.56
2025-10-22	NVO	53.38	-29.7	-1294.2	23.48
2025-10-23	NVO	53.22	-29.7	-655.3	23.48
2025-10-24	NVO	52.98	-29.7	-724.5	23.48
2025-10-27	NVO	52.89	-29.7	-704.4	23.48
2025-10-28	NVO	52.05	-29.7	-1046.7	23.52
2025-10-29	NVO	51.39	-29.7	-1186.2	23.52
2025-10-30	NVO	50.04	-29.7	-1199.8	23.52
2025-10-31	NVO	49.46	-29.7	-706.2	23.52
2025-11-03	NVO	49.11	-30.7	-54.3	23.51
2025-11-04	NVO	48.25	-30.7	-205.3	23.51
2025-11-05	NVO	48.46	-30.7	281.6	23.51
2025-11-06	NVO	46.50	-30.7	-1575.9	23.48
2025-11-07	NVO	45.68	-30.7	-658.3	23.48
2025-11-10	NVO	45.94	-6.9	1049.4	23.48
2025-11-11	NVO	49.15	-6.9	1857.2	22.90
2025-11-12	NVO	50.27	-6.9	743.0	22.90
2025-11-13	NVO	49.15	-7.4	-1046.5	22.87
2025-11-14	NVO	48.25	-7.4	-1405.9	22.87
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	NVO	0	-1.46	0.93
2025-10-21	NVO	0	-1.46	0.93
2025-10-22	NVO	0	-1.46	0.93
2025-10-23	NVO	0	-1.46	0.93
2025-10-24	NVO	0	-1.46	0.93
2025-10-27	NVO	0	-1.50	0.79
2025-10-28	NVO	0	-1.50	0.79
2025-10-29	NVO	0.00	-1.50	0.79
2025-10-30	NVO	0.00	-1.50	0.79
2025-10-31	NVO	0.00	-1.50	0.79
2025-11-03	NVO	0.00	-1.50	0.79
2025-11-04	NVO	0.00	-1.50	0.79
2025-11-05	NVO	0.00	-1.50	0.79
2025-11-06	NVO	0.00	-1.50	0.79
2025-11-07	NVO	0.00	-1.50	0
2025-11-10	NVO	0.00	-1.93	0.79
2025-11-11	NVO	0.00	-1.93	0.79
2025-11-12	NVO	0.00	-1.93	0.84
2025-11-13	NVO	0.00	-1.93	0.84
2025-11-14	NVO	0.00	-1.93	0.84
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

1.02

Avg. EPS Est. Current Quarter

5.87

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-1.93

Beta

0.67

Average Sales Estimate Current Quarter

78324

Average Sales Estimate Next Quarter

76155

Fair Value

57.15

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

67.4

Max Drawdown 5-Year %

-68.5

Target Price

63.25

P/E

14.06

Forward P/E

12.92

PEG

1.79

P/S

3.48

P/B

8.02

P/Free Cash Flow

16.25

EPS

3.43

Average EPS Est. Cur. Y

22.87

EPS Next Y. (Est.)

22.88

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

32.76

Relative Volume

0.8

Return on Equity vs Sector %

34.2

Return on Equity vs Industry %

24.5

EPS 1 7Days Diff

-0.6

EPS 1 30Days Diff

-0.73

EBIT Estimation

-1405.9

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 78554

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

Ascendis Pharma A/S

ASND

$217.98

Name : Ascendis Pharma A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $13,317,870,592.00

EPSttm : -4.44

Ascendis Pharma A/S

$217.98

6.64%

$13.58

Float Short %

5.9

Margin Of Safety %

Put/Call OI Ratio

0.45

EPS Next Q Diff

1.46

EPS Last/This Y

4.32

EPS This/Next Y

6.54

Price

204.51

Target Price

255.17

Analyst Recom

Performance Q

5.32

Relative Volume

2.38

Beta

0.44

Ticker: ASND

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	ASND	205.21	0.43	1.18	5750
2025-10-21	ASND	200.39	0.47	0.96	6277
2025-10-22	ASND	202.98	0.47	0.21	6278
2025-10-23	ASND	201.27	0.47	0.56	6324
2025-10-24	ASND	201.87	0.47	0.11	6337
2025-10-27	ASND	203.18	0.47	0.18	6363
2025-10-28	ASND	206.54	0.47	0.91	6395
2025-10-29	ASND	205.88	0.47	0.33	6407
2025-10-30	ASND	203.63	0.47	0.00	6410
2025-10-31	ASND	201.46	0.47	14.18	6442
2025-11-03	ASND	201.03	0.50	0.68	6606
2025-11-04	ASND	208.35	0.50	0.42	6640
2025-11-05	ASND	197.27	0.50	0.35	6655
2025-11-06	ASND	199.52	0.50	0.08	6724
2025-11-07	ASND	197.7	0.50	6.68	6723
2025-11-10	ASND	195.95	0.53	8.88	6850
2025-11-11	ASND	200.84	0.52	0.20	6819
2025-11-12	ASND	200.09	0.49	0.24	7239
2025-11-13	ASND	206.63	0.47	0.20	8184
2025-11-14	ASND	204.4	0.45	0.27	10073
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	ASND	205.21	85.0	418.5	-2.51
2025-10-21	ASND	200.32	85.0	418.7	-2.51
2025-10-22	ASND	202.70	86.9	425.6	-2.39
2025-10-23	ASND	201.07	86.9	421.8	-2.39
2025-10-24	ASND	201.76	86.9	424.1	-2.39
2025-10-27	ASND	203.15	86.9	424.3	-2.39
2025-10-28	ASND	205.91	86.9	425.8	-2.39
2025-10-29	ASND	205.60	86.9	422.7	-2.39
2025-10-30	ASND	203.71	90.8	420.7	-2.21
2025-10-31	ASND	201.60	90.8	420.9	-2.21
2025-11-03	ASND	201.04	90.8	422.3	-2.21
2025-11-04	ASND	208.30	90.8	430.1	-2.21
2025-11-05	ASND	197.11	90.8	411.6	-2.21
2025-11-06	ASND	199.22	90.8	420.5	-2.21
2025-11-07	ASND	197.74	90.8	416.8	-2.21
2025-11-10	ASND	196.01	90.8	416.5	-2.21
2025-11-11	ASND	201.16	90.8	423.6	-2.21
2025-11-12	ASND	200.15	90.8	417.2	-2.21
2025-11-13	ASND	206.50	90.8	424.1	-2.21
2025-11-14	ASND	204.51	93.8	376.0	-3.28
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	ASND	0.00	-3.53	4.26
2025-10-21	ASND	0.00	-3.53	4.26
2025-10-22	ASND	0.00	-3.53	4.26
2025-10-23	ASND	0.00	-3.53	4.26
2025-10-24	ASND	0.00	-3.53	4.26
2025-10-27	ASND	0.00	-3.32	5.69
2025-10-28	ASND	0.00	-3.32	5.69
2025-10-29	ASND	0.00	-3.32	5.69
2025-10-30	ASND	0.00	-3.32	5.69
2025-10-31	ASND	0.00	-3.32	5.69
2025-11-03	ASND	0.00	-3.41	5.69
2025-11-04	ASND	0.00	-3.41	5.69
2025-11-05	ASND	0.00	-3.41	5.69
2025-11-06	ASND	0.00	-3.41	5.69
2025-11-07	ASND	0.00	-3.41	5.69
2025-11-10	ASND	0.00	-5.52	5.69
2025-11-11	ASND	0.00	-5.52	5.69
2025-11-12	ASND	0.00	-5.52	5.90
2025-11-13	ASND	0.00	-5.52	5.90
2025-11-14	ASND	0.00	-5.52	5.90
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-0.04

Avg. EPS Est. Next Quarter

0.29

Insider Transactions

Institutional Transactions

-5.52

Beta

0.44

Average Sales Estimate Current Quarter

236

Average Sales Estimate Next Quarter

280

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

5.5

Max Drawdown 5-Year %

-61.7

Target Price

255.17

P/E

Forward P/E

51.02

PEG

P/S

17.17

P/B

P/Free Cash Flow

EPS

-4.25

Average EPS Est. Cur. Y

-3.28

EPS Next Y. (Est.)

3.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-35.52

Relative Volume

2.38

Return on Equity vs Sector %

106.9

Return on Equity vs Industry %

121.7

EPS 1 7Days Diff

-1.1

EPS 1 30Days Diff

-0.69

EBIT Estimation

376

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y